EAM Investors LLC decreased its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 9.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 268,514 shares of the medical instruments supplier’s stock after selling 26,835 shares during the period. OraSure Technologies makes up approximately 0.8% of EAM Investors LLC’s holdings, making the stock its 6th largest position. EAM Investors LLC owned approximately 0.45% of OraSure Technologies worth $6,042,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of OraSure Technologies by 127,593.4% during the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after buying an additional 7,737,261 shares during the period. Vanguard Group Inc. lifted its position in OraSure Technologies by 19.8% in the second quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock valued at $92,390,000 after purchasing an additional 886,333 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of OraSure Technologies by 5.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,057,690 shares of the medical instruments supplier’s stock valued at $52,777,000 after acquiring an additional 167,642 shares during the period. Daruma Capital Management LLC lifted its position in shares of OraSure Technologies by 2,761.0% during the 2nd quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after acquiring an additional 2,722,886 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of OraSure Technologies by 32.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after acquiring an additional 452,642 shares during the period. Institutional investors and hedge funds own 94.41% of the company’s stock.
WARNING: “EAM Investors LLC Sells 26,835 Shares of OraSure Technologies, Inc. (OSUR)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/20/eam-investors-llc-sells-26835-shares-of-orasure-technologies-inc-osur.html.
In other OraSure Technologies news, CEO Douglas A. Michels sold 25,000 shares of OraSure Technologies stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the sale, the chief executive officer now directly owns 743,058 shares of the company’s stock, valued at approximately $16,755,957.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,110 shares of company stock valued at $1,362,463. Corporate insiders own 6.40% of the company’s stock.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group LLC reiterated a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $18.21.
Shares of OraSure Technologies, Inc. (NASDAQ OSUR) traded down $0.35 on Monday, hitting $13.74. 1,199,100 shares of the stock were exchanged, compared to its average volume of 871,565. OraSure Technologies, Inc. has a fifty-two week low of $8.21 and a fifty-two week high of $23.01. The stock has a market cap of $833.31, a PE ratio of 26.42, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. During the same period last year, the company posted $0.11 EPS. The company’s revenue was up 31.0% on a year-over-year basis. analysts expect that OraSure Technologies, Inc. will post 0.42 earnings per share for the current year.
OraSure Technologies Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.